Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
Trial ID or NCT#
Status
Purpose
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.
Official Title
Expanded Access Protocol for Product Which Does Not Conform to the TECELRA® (Afamitresgene Autoleucel, Suspension for Intravenous Infusion) Commercial Release Specification
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Melanie G San Pedro-Salcedo
650-724-1388
View on ClinicalTrials.gov